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Background and Purpose: To determine the availability of outcomes data to head and neck 
cancer patients. To create a database of comprehensive information including demographics, 
process metrics, and outcomes for head and neck cancer patients who were diagnosed or 
treated at a Yale New Haven Hospital affiliate. To examine factors affecting functional and 
patient reported outcomes in patients with oropharyngeal cancers. 
Materials and Methods: The websites of all NCI-designated Cancer Centers and all affiliated 
institutions were examined for publicly available data regarding head and neck cancer patients. 
For Yale data, IRB approval was obtained to use tumor registry data, as well as chart review, to 
create a comprehensive database for all new head and neck cancer patients at Yale in 2013 and 
2014. The patients with oropharyngeal cancers were then isolated and all living patients were 
called to survey them about long term treatment effects, using a standardized survey. The data 
gathered was then analyzed using univariate and multivariate analysis. 
Results: Only 6 institutions across the country had any publicly available data regarding head 
and neck patients, and only three of them had information beyond the number of patients seen. 
The database of head and neck cancer patients at Yale was created successfully, and compiled 
into outcomes books for each year that presented the relevant data. Analysis of oropharyngeal 
patients focused on HPV status, insurance type, academic vs. non-academic centers, and 
distance from radiation treatment site for patients treated with that modality. Many factors 
were found to be significant on univariate analysis. On multivariate analysis, it was found that 
HPV positive patients had better outcomes in various functional and patient reported outcomes. 
It was also found that private practice patients had improved outcomes compared to Medicare 
patients. Finally, it was also found that recurrence rates were higher for patients that lived over 
15 miles away from their treatment site. 
Conclusions: There is a paucity of publicly available data regarding head and neck cancer 
outcomes at NCI designated cancer centers around the country. At Yale, the data showed that 
standard metrics are in line with national outcomes. The institution can improve significantly in 
terms of various process metrics, most specifically in terms of having various ancillary staff work 
with patients who are diagnosed or treated for a head or neck cancer. Analysis of oropharyngeal 
patients demonstrated that patients with HPV negative cancers need closer monitoring for 
various functional and patient reported outcomes. It also demonstrated that patients on 
Medicare need monitoring for various other functional and patient reported metrics. Patients 
who live further from their treatment sites have higher recurrence rates, indicating that patients 
who have to travel further might be at higher risk for missing treatment or for receiving 
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Head and Neck (H&N) cancers account for approximately 3 percent of cancers annually. 
This translates to over 50,000 new diagnoses annually. When patients receive a 
diagnosis of head or neck cancer, many of them want more comprehensive data about 
their diagnosis, but are unable to obtain specific data about the prognosis of their 
specific pathology, both in terms of morbidity and mortality. For most patients, local 
referral patterns and Internet searches are the most common ways to seek further 
evaluation and treatment. However, despite the frequency of these cancers, there is 
relatively little data available to patients pertaining to the outcomes they can expect.  
National Data 
Many of these patients are seen and treated at NCI-designated cancer centers, of which 
there are currently 62 sites that provide patient care including 45 NCI-designated 
Comprehensive Cancer Centers and 17 NCI-designated Cancer Centers.  All of these 
centers have programs dedicated to H&N cancers; however, the public availability of 
information on quality of care, including basic structural, process, and outcome metrics 
amongst these centers has never been systematically analyzed. We hypothesized that 
there was almost no data available for each cancer center on their individual metrics.  
Yale Database 
At Yale, approximately 200 head and neck cancer patients are diagnosed or treated at 
Yale New Haven Hospital or an affiliated hospital annually. This includes cancers found 
in the oral cavity, salivary glands, larynx, and pharynx (including nasopharynx, 
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oropharynx, and hypopharynx). In addition, while there is some national data available 
broadly, treatment center specific data at Yale is unavailable.  
This project aimed to analyze the feasibility of providing comprehensive outcomes data 
to providers and patients about how our program performed. The data analyzed was 
based on the American Association of Head and Neck Surgery guidelines. This is based 
on evidence based reviews showing optimal outcomes for patients diagnosed with head 
and neck cancers. The analysis was broken into three main categories, with a number of 
subcategories. The three main categories were structural, process, and outcome 
metrics.  
Oropharyngeal Patients 
In recent years, it has become apparent that in order to maximize value to the patient, 
health care providers must work to provide care that minimizes morbidity and mortality, 
while also attempting to maximize patient quality of life. Traditionally, quality was 
measured through functional outcomes that could be quantified. However, in recent 
years, the use of patient reported surveys has become more common, and has been 
shown to be strongly correlated with patient quality of life. There have been many 
studies that report morbidity and mortality outcomes for head and neck cancer 
patients.1-3 Other studies have focused on differences in outcomes based on a variety of 
patient, tumor, and treatment variables. One recent area of focus has been HPV positive 
cancers. There have been numerous studies that show that HPV positive cancers have 
significantly improved survival4-7, as well as decreased rates of progression8 and 
improved responses to treatment9-12 compared to HPV negative ones. However, there 
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have only been three studies13-15, to our knowledge, that have analyzed differences in 
patient reported quality of life based on HPV status. There has been only one study that 
analyzed age, gender, and stage differences in quality of life outcomes in oral cavity and 
oropharyngeal cancers16, though others have analyzed survival and treatment 
response10,17 No studies, to our knowledge, have analyzed both objective quality of life 
outcomes as well as patient reported outcomes in oropharyngeal cancers based on a 
variety of patient, tumor and treatment factors, which was one of the goals of this 
study. 
Patient Reported Outcomes 
Patients with head and neck cancers have traditionally had a wide variety of functional 
problems, such as problems with speech and/or swallowing, pain management, and 
social burden. Many of these problems have not been measured in traditional studies, 
but has been measured more recently through patient surveys. A validated head and 
neck patient reported outcomes measurement tool, the EORTC-35, has been used to 
examine patient quality of life during and after treatment for head and neck cancers. 
One major goal of this study was to assess the long-term quality of life for patients with 
oropharyngeal cancers. 
Statement of Purpose 




2. To create a comprehensive database of all analytic patients in 2013 and 2014 treated at 
a Yale New Haven Hospital 
3. To compile oropharyngeal patient data for functional outcomes, and analyze that data 
for key metrics that may affect outcomes 
4. To gather patient reported outcomes for oropharyngeal patients, and analyze it for key 
metrics that affect outcomes. 
Materials and Methods 
National Data 
In order to analyze the data that is available to patients, the websites of the NCI 
designated 45 Comprehensive Cancer Centers, as well as the 17 Cancer Centers across 
the US were searched for any outcomes data that would be accessible to patients. The 
affiliated universities and hospitals were searched for the same information. That data 
was then compiled all the data into structural, process, and outcome metrics. PubMed 
was not used, as the articles in it are not easily accessible to patients. 
Yale Database 
For the second part of this study, functional outcomes were examined for 
oropharyngeal patients at Yale. IRB approval was obtained to conduct a study examining 
all oropharyngeal patients in 2013 and 2014, which would involve analyzing data about 
them, as well as contacting them to obtain patient reported outcomes data. In order to 
analyze the vast amount of data to present comprehensive data to our patients and 
providers, the tumor registry data was used as a starting point. The registry was able to 
provide all head and neck cancer patients who had been seen at a Yale affiliated 
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hospital broken down by year. Thyroid cancer cases were specifically excluded for this 
analysis, as many thyroid cases at Yale are treated by the endocrine surgery 
department. In order to verify that the data gathered by the tumor registry was 
accurate, a manual analysis of every patient seen by a head and neck cancer surgeon in 
2014 was done. This involved looking at the four head and neck cancer surgeons in 
2014, and cataloguing every new patient that they saw. All patients who were 
subsequently diagnosed with cancer were then compared to the data the tumor registry 
had on file. It was found that the data matched up, so all patients provided by the tumor 
registry were used. Only analytic patients (those diagnosed and/or treated at a Yale 
facility) were included in the analysis. The following data was gathered for each patient: 
Structural metrics are defined as information that assesses the basic characteristics of 
the patient, the pathology, and the treatment received. 
• Patient factors 
o Age 
o Gender 
o insurance status 
o geographic location  
• Tumor factors 
o site of tumor 
o type of tumor 
o stage 
o HPV status 
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• Treatment factors 
o types of treatment 
o Hospital where patient received treatment 
o Type of chemotherapy 
o Academic vs Non-academic treatment site 
o Distance from Radiation treatment site 
Process metrics measure whether the care provided is consistent with routine clinical 
care. 
• pre-treatment 
o physical exam 
o head or neck CT or MRI 
o chest imaging 
o audiogram 
o speech and swallow evaluation 
o dental evaluation 
o nutrition consult 
o staged before treatment 
o clinically staged 
o pathology was reviewed at a Cancer Center 
o reviewed by the multidisciplinary tumor board. 
• Treatment 
o number of lymph nodes removed (if they underwent surgery) 
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o positive margins 
o times to treatment 
▪ diagnosis to treatment 
▪ surgery to adjuvant therapy 
▪ radiation therapy  
▪ total treatment  
 
• post-treatment 
o 1 year follow-up 
o CT/MRI 3-6 months after treatment 
o TSH 1 year after treatment 
o Dental follow-up 
Outcomes metrics involved morbidity and mortality assessments, as well as how 
effective Yale physicians were at stopping detrimental habits such as smoking and 
drinking. 
• Mortality 
o 1 year overall survival (OS) 
o 1 year disease specific survival (DSS) 
o 1 year disease free survival (DFS) 
• Surgical complications 




o 30-day readmission 
o Positive surgical margins 
• Oncological complications 
o Admission during chemotherapy or radiation 
o Salvage Surgery 
o Renal damage 
o Hearing loss 
• Functioning 
o Gastrostomy tube during treatment 
o Tracheostomy during treatment 
o Gastrostomy six months after treatment 
o Tracheostomy six months after treatment 
• Habits 
o Smoker at diagnosis 
o Alcoholic at diagnosis 
o Smoker six months after treatment 
o Alcoholic six months after treatment 
Yale switched to EMR in late 2012, so data gathering began in 2013. The categories 
highlighted above were able to be obtained from the tumor registry, or information 
from the registry was analyzed in order to yield the relevant information. For instance, a 
description of the imaging input by the tumor registry was used to determine which 
patients had head or neck imaging, or chest imaging. Durations were obtained by 
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analyzing start and end dates of various diagnoses and treatments. Other metrics were 
able to be obtained directly from tumor registry data without further analysis. For the 
categories obtained from EPIC, chart review was required to obtain the necessary data.  
The data that was gathered was fairly comprehensive, but there were many 
assumptions that had to be made in order to have complete data. The list of 
assumptions include: 
• HPV status: non-squamous cell carcinoma cases were assumed to be negative 
• Staged before treatment: Only counted if documented in EPIC 
• Overall stage: Based on pathological stage if possible, otherwise clinical stage 
was used 
• Academic vs. Non-academic: If a patient received any treatment at a non-Yale 
affiliated treatment site, they were classified as non-academic 
• Head and Neck imaging/Chest imaging: If patient received a PET exam, both 
were counted 
• Pathology reviewed at Yale: If pathology note was Smilow Cancer Center, St. 
Raphael’s Hospital, or Bridgeport Hospital, it was counted (facilities directly 
owned by Yale) 
• Audiogram/Nutrition/Speech Language Pathology/Dental: Only counted if 
documented in the chart (private dentists or nutritionists were not included, as 
private providers do not participate in the multidisciplinary treatment team)  
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• Multidisciplinary Tumor Board: Counted if included on the Weekly Tumor Board 
list 
• Lymph nodes removed: Yield based on pathology report. This is only based on 
initial surgery, not any subsequent procedures. 
• Date of last contact: any patients who had not been seen in over one year at the 
date of analysis were contacted by the tumor registry for follow-up data 
• CT/MRI after treatment: Only included if strictly between 3 to 6 months after 
treatment 
• TSH after treatment: Only includes analysis of radiation therapy patients who 
had TSH strictly between 11 and 13 months after treatment 
• Dental (post treatment): Only if included in chart 
• 1 year follow-up: Patients must have had at least 3 appointments in the year 
following treatment, each visit at least 2 months apart). If patients died before 1 
year, they were not counted. 
• 1 year Overall survival: If patients were unable to be followed up, they were 
considered alive 
• 1 year disease specific survival: Unless patients were documented to have cancer 
at time of death, they were counted for disease specific survival 
• 1 year recurrence: Patients counted only if they had documented recurrence at 1 
year. Unknown patients were not counted. 
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• Renal Injury/Hearing Loss: cisplatin treated patients that had any documented 
renal injury (Creatinine clearance increase by 0.3) or hearing loss during 
treatment with cisplatin 
• Tracheostomy during treatment: If patients received tracheostomy during 
surgery, but it was removed before patient was discharged, it was not included. 
• Gastrostomy tube/tracheostomy six months after treatment: If patients expired 
before six months passed, they were not counted. 
• Smoker/alcoholic six months after treatment: If patients expired before six 
months passed, they were not counted. 
Once the data had been gathered, it was compiled into different tables and graphs. 
Using Excel’s PivotTable function, patients were sorted into various categories. Almost 
all structural metrics were graphed using all patients. HPV status was an exception to 
this, as oropharyngeal HPV status was measured separately from the overall population. 
For all process and outcome metrics, overall percentages were measured, but each 
metric was then further broken down into early (defined as stage 1 or 2) and late 
(defined as stage 3 or 4) stage cancers. 
Oropharyngeal Patients 
The data for oropharyngeal patients was extracted from the Yale Database that was created by 
isolating patients who had cancers of the tonsil, soft palate, base of tongue, or general 
oropharyngeal area, as detailed by the tumor registry. 
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Patient Reported Outcomes 
For the patient reported section of the data, the physicians for all patients who were 
currently alive were contacted to obtain permission to communicate with their patients. 
Only patients who had at least one Yale physician (as opposed to all private physicians) 
were contacted. Each patient was then sent a letter through the mail detailing basic 
elements of the study, and allowing them to opt out of the study. The patients were 
then phoned by the thesis author, as well as another medical student, and were then 
asked to give verbal consent to conduct the study. If the patient approved, the EORTC-
35 would then be conducted over the phone.  
The patient reported outcomes is presented similarly to the functional outcomes, but 
had to first be converted into a standardized format. This was necessary because each 
of the first 30 questions are rated on a 1-4 scale, while the remaining 5 are binary 
yes/no questions. In addition, creating different categories for each of the 35 questions 
becomes difficult to understand and to find patterns. Finally, different categories have 
different numbers of questions, which would lend greater weight to some categories, 
and less to others. By using a standardized format, we aimed to avoid these problems. 
The EORTC QLQ-H&N35 was divided into 7 scales (pain, swallowing, sense, speech, 
social eating, social contact and sexuality) and transformed into a 0-100 scale, with 0 
representing no problems with the aforementioned categories, and 100 representing 
severe problems. There were also 11 single items that were assessed separately, but 
using the same scoring system, as they do not fall into the previous categories (having to 
do with teeth problems, opening mouth, dry mouth, sticky saliva, coughing, feeling ill, 
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intake of painkillers, nutritional supplements, feeding tube, weight loss and weight 
gain). This scaling model is standardized and was originally proposed by the survey 
creators18 and has been used numerous times since then. There are different number of 
questions for each of the 7 scales, as follows: 
category questions number 
of 
questions 
pain 1-4 4 
swallowing 5-8 4 
sense 13-14 2 
speech 16, 23-24 3 
social eating 19-22 4 
social contact 18, 25-28 5 
sexuality 29-30 2 
teeth problems 9 1 
opening mouth 10 1 
dry mouth 11 1 
sticky saliva 12 1 
coughing 15 1 
feeling ill 17 1 






feeding tube 33 1 
weight loss 34 1 
weight gain 35 1 
 
Each of the first 30 questions was ranked on a 0-3 scale. For the 7 multiple question 
scales, the score of all questions in that category was summed then divided by the 
maximum possible score to get to a percentage that fit into the 0-100 scale. For the final 
five questions, the choice was binary. Those questions were therefore treated similarly 
to the functional outcomes metrics above, in that the aggregate score was simply a 
percentage. Once the categories were standardized, they could be treated similarly to 




Of the 62 centers examined, 6 reported one or more H&N cancer quality or outcome 
metric (figure 1). Three of the six, Memorial Sloan Kettering Cancer Center, University of 
Iowa, and University of North Carolina reported the total number of patients seen.  The 
other three (Massachusetts Eye and Ear Infirmary, Mount Sinai Health System, and 
Cleveland Clinic) had outcomes books with 2-4 pages pertaining to quality and outcome 
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metrics for H&N cancer. MEEI reported total number of free flaps (FF), type of 
antibiotics used in FF-cases, surgical site infection rate after FF surgery, and functional 
shoulder outcomes after a supraclavicular artery island flap.  Cleveland reported type of 
FF used; FF success rates, length of stay for FF patients; outcome metrics for late-stage 
supraglottic cancers (larynx preservation rates, freedom from recurrence, overall 
survival, voice scores, and swallowing scores), late-stage p16+ oropharyngeal carcinoma 
(OS and DSS rates), and voice restoration with TEP.  Mount Sinai reported complications 
rates after robotic surgery. 
 
Yale Database 
The data at Yale was compiled successfully, though initial data gathering took significant 
amounts of time. In the initial examination of all patients seen by the head and neck 
surgeons at Yale for 2014 (in order to verify the reliability of tumor registry data), over 
600 patients were catalogued. 242 were found to have a malignancy and were analytic 
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patients, and therefore included in the final analysis. Two comprehensive outcomes 
books (one for 2013 and one for 2014) focused on head and neck cancer were created 
from the data. The outcomes book was broken down into three sections. The first 
section contained basic information regarding head and neck cancers. The second 
section contained data concerning structural and process metrics. The final section 
contained the outcomes data. Each outcomes book is presented below, with the first 





2013 Smilow – Yale New Haven Health 




















Part B: Structural Metrics 
• 215 patients analyzed throughout the Yale-New Haven Hospital system 
o patients who received their diagnosis and/or their initial treatment at a Yale-New Haven Hospital 
affiliate 
o patients were weeded out if there was no information found in the electronic medical record, EPIC 
• 19 hospitals included 
o YNHH System hospitals: Yale-New Haven, St. Raphael’s, or Bridgeport Hospital, all of which are under 
the YNHH system 
o Other hospitals: West Haven Veteran’s Affairs hospital, Lawrence and Memorial, Hartford Hospital, 
Greenwich Hospital, Memorial Sloan Kettering, Griffin Hospital, Danbury Hospital, Charlotte Hungerford 
Hospital, St. Anne’s Hospital, Waterbury Hospital, Stamford Hospital, New York Medical Center, 
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hypopharynx, 17, 8%
salivary gland, 19, 
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oropharynx, 86, 41%
oral cavity, 79, 38%



















stage 0, 4, 2%
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• Surgery at a YNHH hospital (164 patients) 
• 123 received all subsequent treatment (including no further treatment) at YNHH 
• 14 other sites locations for adjuvant therapy 















































43 15 2 9 3 






Surgical Data: Recent data from a large study done at Yale recommends that if elective neck dissection occurs, the 
patients who have more than 17 lymph nodes removed have a better outcome.  
• 73 out of 102 patients had 18 or more nodes removed on one side 
• 15 patients who had bilateral neck dissections 
• Each side of the neck as a separate procedure, which brought our total neck dissections to 117  














• 210 patients received treatment, the average length of time from diagnosis to treatment was 37 days.  
• 93 patients who received adjuvant therapy after surgery. The average time from surgery to adjuvant therapy 
was 51 days. 
• 130 patients who received radiation treatment. The average duration of treatment was 48 days. 
• The average of the total duration of treatment was 85 days. Surgery only patients excluded from overall data, 












































• AAHNS guidelines recommends that all patients receive a CT or MRI of their head and neck between 3 and 6 
months after the conclusion of their treatment.  
• It is also recommended that patients who underwent radiation therapy receive a TSH screening 11-13 after the 
conclusion of their treatment. In 2013, there were 131 patients who had radiation therapy.  
• Patients are also at risk of dental issues after treatment, with dental follow-up recommended.  
• Appropriate follow-up after 1 year defined as at least 3 visits at least 2 months apart.  
215 
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• 26 patients had a tumor recurrence, with 13 having local recurrence, 11 with regional recurrence, and 10 with 
distant recurrence (several patients were noted to have recurrence in multiple sites).  
•  31 cases of progressive cancer.  
215 
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• 6 patients had to be readmitted within 30 days after surgery.  
• 1 patient with a surgical site infection.  
• 2 patients who had a flap-loss out of 40 patients.  
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• 88 patients who received cisplatin based chemotherapy, and were included when assessing renal damage or 
hearing loss  
6 9 2  0 3 





• 62 patients had a percutaneous endoscopic gastrostomy (PEG) tube  
• 10 patients had a tracheostomy during treatment. Any patients who received a tracheostomy during surgery 
that was removed before discharge were not counted.  
• 24 patients had a PEG 6 months after treatment  
• 4 patients had a tracheostomy 6 months after treatment 
215 
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• 61 patients were smokers at diagnosis 
• 26 patients were alcoholics at diagnosis 
• 19 patients were smokers 6 months after treatment conclusion 
• 16 patients were alcoholics 6 months after treatment conclusion 
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2014 Smilow – Yale New Haven Health 



















Part B: Structural Metrics 
• 242 patients analyzed throughout the Yale-New Haven Hospital system 
o patients who received their diagnosis and/or their initial treatment at a Yale-New Haven Hospital 
affiliate 
o patients were weeded out if there was no information found in the electronic medical record, EPIC 
• 19 hospitals included 
o YNHH System hospitals: Yale-New Haven, St. Raphael’s, or Bridgeport Hospital, all of which are under 
the YNHH system 
o Other hospitals: West Haven Veteran’s Affairs hospital, Lawrence and Memorial, Danbury Hospital, 
Charlotte Hungerford Hospital, St. Francis Hospital, Backus Hospital, Harold Leever National Cancer 
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• Surgery at a YNHH hospital (180 patients) 
• 141 received all subsequent treatment (including no further treatment) at YNHH 
• 12 other sites locations for adjuvant therapy 
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Surgical Data: Recent data from a large study done at Yale recommends that if elective neck dissection occurs, the 
patients who have more than 17 lymph nodes removed have a better outcome.  
• 98 out of 127 patients had 18 or more nodes removed on one side 
• 15 patients who had bilateral neck dissections 
• Each side of the neck as a separate procedure, which brought our total neck dissections to 142.  




















• 231 patients received treatment, with 29 days as the average length of time from diagnosis to treatment. 
• 96 patients who received adjuvant therapy after surgery. The average time from surgery to adjuvant therapy 
was 43 days. 
• 130 patients who received radiation treatment. The average duration of treatment was 47 days. 
• The average of the total duration of treatment was 78 days. Surgery only patients excluded from overall data, 











































































• AAHNS guidelines recommends that all patients receive a CT or MRI of their head and neck between 3 and 6 
months after the conclusion of their treatment.  
• It is also recommended that patients who underwent radiation therapy receive a TSH screening 11-13 after the 
conclusion of their treatment. In 2014, there were 132 patients who had radiation therapy.  
• Patients are also at risk of dental issues after treatment, with dental follow-up recommended.  
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• 31 patients had a tumor recurrence, with 22 having local recurrence, 15 with regional recurrence, and 11 with 
distant recurrence (several patients were noted to have recurrence in multiple sites).  
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• 14 patients had to be readmitted within 30 days after surgery.  
• 12 patients with a surgical site infection.  
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• 73 patients who received cisplatin based chemotherapy, and were included when assessing renal damage or 
hearing loss  
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• 58 patients had a percutaneous endoscopic gastrostomy (PEG) tube  
• 10 patients had a tracheostomy during treatment. Any patients who received a tracheostomy during surgery 
that was removed before discharge were not counted.  
• 36 patients had a PEG 6 months after treatment  
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• 71 patients were smokers at diagnosis 
• 34 patients were alcoholics at diagnosis 
• 19 patients were smokers 6 months after treatment conclusion 
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The oropharyngeal patients were then isolated from this initial data set. The structural data for all 162 
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PEG-tube during treatment Tracheostomy during
treatment
PEG-tube 6 months after
treatment






Smoker during treatment Alcoholic during treatment Smoker 6 months after
treatment





Based on this data, it was decided to focus on four independent variables, academic vs. 
non-academic treatment, distance from radiation treatment site, HPV status, and 
insurance type. The outcomes data was then analyzed for mean values across those 
variables. They are shown in the table below, with the number of patients of each type 
at the bottom: 
 
Univariate analysis was conducted for the independent variables found in the table 
above against the functional outcomes that were documented through tumor registry: 
Closer than 15 miles Greater than 15 miles HPV Positive HPV Negative Academic Non-academic Private Medicare Medicaid Uninsured Other
Overall Survival 90.9% 96.4% 92.6% 69.2% 88.9% 88.9% 92.4% 78.3% 92.3% 100.0% 95.0%
Disease Specific Survival 90.9% 96.4% 92.6% 69.2% 88.9% 88.9% 92.4% 78.3% 92.3% 100.0% 95.0%
Disease Free Survival 84.8% 74.5% 78.7% 53.8% 74.4% 75.0% 79.7% 60.9% 92.3% 50.0% 80.0%
Recurrence Rate 4.9% 21.2% 12.0% 26.3% 16.9% 9.8% 13.3% 21.6% 0.0% 0.0% 11.1%
Surgical Site Infection 1.5% 1.8% 1.5% 3.8% 1.1% 2.8% 1.3% 4.3% 0.0% 0.0% 0.0%
Flap Loss 0.0% 0.0% 0.7% 0.0% 0.0% 1.4% 1.3% 0.0% 0.0% 0.0% 0.0%
30 Day Readmission 4.2% 5.7% 6.2% 6.7% 7.0% 5.5% 3.4% 10.7% 0.0% 25.0% 6.7%
Admission during ChemoXRT 12.1% 14.5% 14.1% 7.7% 16.9% 8.3% 11.4% 15.6% 23.1% 25.0% 5.0%
Salvage Surgery 3.0% 3.6% 4.4% 3.8% 4.4% 4.2% 3.8% 2.2% 0.0% 0.0% 15.0%
Renal Damage 14.8% 9.1% 13.6% 0.0% 11.8% 11.3% 9.5% 21.2% 0.0% 0.0% 6.3%
Hearing Loss 1.9% 4.5% 1.0% 16.7% 2.9% 3.8% 3.2% 0.0% 14.3% 0.0% 6.3%
G tube during treatment 54.5% 34.5% 39.0% 57.7% 45.6% 37.5% 34.2% 45.7% 46.2% 50.0% 60.0%
Trach during treatment 3.0% 1.8% 2.2% 11.5% 4.4% 2.8% 2.5% 6.5% 7.7% 0.0% 0.0%
G tube after treatment 25.0% 14.0% 17.1% 25.0% 19.5% 16.7% 9.6% 28.9% 9.1% 25.0% 35.3%
Trach after treatment 0.0% 2.0% 0.8% 5.0% 2.6% 0.0% 0.0% 5.3% 0.0% 0.0% 0.0%
Smoker during treatment 36.4% 25.5% 26.5% 65.4% 28.9% 37.5% 25.3% 45.7% 38.5% 25.0% 30.0%
Alcoholic during treatment 10.6% 16.4% 12.5% 15.4% 10.0% 16.7% 8.9% 19.6% 23.1% 25.0% 5.0%
Smoker after treatment 10.0% 10.0% 7.3% 20.0% 10.4% 7.6% 8.2% 7.9% 18.2% 0.0% 11.8%
Alcoholic after treatment 6.7% 12.0% 8.9% 10.0% 9.1% 9.1% 8.2% 13.2% 9.1% 0.0% 5.9%




In the results shown above, any values found to be approaching significance (p<0.2) are 
highlighted in yellow, while any values that were found to be significant (p<0.05) are 
highlighted in green. 
Multivariate analysis was then conducted for Insurance type, HPV status, Academic vs 
Non-academic center, and treatment distance for patients treated with radiation. For 
each of these variables, gender, age, stage, and treatment type were controlled for. The 
results are presented below, with significant variables highlighted in green. 
 
Gender Age Insurance Stage HPV status Treatment type Academic Center Treatment Distance
OS 0.824 0.007 0.06 0.999 0.002 0.002 0.738 0.998
DSS 0.824 0.007 0.06 0.999 0.002 0.002 0.738 0.998
DFS 0.993 0.029 0.029 0.154 0.006 0.003 0.885 0.766
Recurrence 0.808 0.416 0.265 0.999 0.102 0.999 0.286 0.041
SSI 0.552 0.844 0.941 0.999 0.331 0.375 0.546 0.998
Flap Loss 0.999 0.594 0.998 0.999 0.999 0.996 0.999 1
30 day readmission 0.497 0.734 0.139 0.999 0.943 0.368 0.733 0.965
Admission during 
chemoXRT 0.593 0.173 0.112 0.297 0.663 0.207 0.079 0.523
Salvage 0.96 0.097 0.035 0.999 0.998 0.998 0.942 0.258
Renal damage 0.999 0.461 0.273 0.999 0.999 1 0.832 0.757
Hearing Loss 0.403 0.724 0.045 0.999 0.023 1 0.647 0.582
G tube treatment 0.731 0.195 0.104 0.236 0.081 0.298 0.341 0.267
Trach during 
treatment 0.936 0.524 0.289 0.999 0.038 0.999 0.642 0.998
G tube after 
treatment 0.915 0.064 0.348 0.525 0.397 0.056 0.695 0.743
Trach after 
treatment 0.998 0.685 0.999 0.999 0.195 0.81 0.997 0.997
Smoker during 0.831 0.011 0.021 0.803 0 0.03 0.247 0.275
Alcoholic during 0.444 0.998 0.091 0.878 0.689 0.618 0.635 0.55
Smoker after 0.409 0.998 0.999 0.999 0.08 0.999 0.58 0.562

















































Insurance 0.778 0.778 0.12 0.115 0.079 0.999 0.295 0.743 0.998 0.233 0.33 0.783 0.673 0.073 0.997 0.29 0.027 0.306 0.102
HPV 0.024 0.024 0.015 0.096 0.407 0.999 0.869 0.44 0.998 0.999 0.021 0.164 0.067 0.563 0.325 0.001 0.473 0.041 0.79
Academic 0.845 0.845 0.934 0.194 0.668 0.999 0.522 0.092 0.997 0.94 0.658 0.481 0.57 0.784 0.997 0.188 0.336 0.411 0.973
Radiation Distance 0.998 0.998 0.686 0.023 0.998 0.999 0.901 0.449 0.258 0.819 0.568 0.33 0.998 0.817 0.996 0.305 0.48 0.508 0.754
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In the data above, Insurance type is found to be significant for alcoholic during 
treatment. This was found to be significant when comparing private insurance against 
Medicare patients. 
Patient Reported Outcomes 
There were 55 patients who completed the survey. Other patients could not be reached 
despite repeated attempts, or declined to participate. The mean time since treatment 
complete was 32.27 ± 6.71 months. The data was broken down similarly to above, based 
on Treatment distance, HPV status, Academic vs Non-academic center, and distance to 
radiation treatment site. 
 
Closer than 15 miles Greater than 15 miles HPV Positive HPV Negative Academic Non-academic Private Medicare Medicaid Uninsured Other
Pain 0.0% 9.8% 5.9% 25.0% 7.8% 6.4% 5.1% 14.4% 2.8% 0.0% 4.2%
Swallowing 17.8% 18.2% 14.9% 54.2% 19.2% 15.5% 13.6% 32.2% 2.8% 8.3% 8.3%
Senses Problems 27.3% 14.4% 16.3% 50.0% 20.7% 15.9% 16.2% 30.0% 0.0% 16.7% 8.3%
Speech Problems 18.7% 13.1% 12.2% 72.2% 15.8% 17.7% 9.1% 32.6% 7.4% 38.9% 11.1%
Trouble with social eating 22.3% 12.1% 15.2% 66.7% 22.0% 14.4% 13.9% 35.6% 5.6% 16.7% 0.0%
Trouble with Social Contact 6.4% 3.6% 4.3% 25.0% 8.7% 1.5% 4.0% 12.0% 0.0% 0.0% 3.3%
Less Sexuality 15.2% 12.9% 12.7% 0.0% 15.2% 6.8% 8.1% 14.4% 5.6% 0.0% 75.0%
Teeth 28.8% 18.2% 22.2% 8.3% 25.3% 15.2% 25.3% 22.2% 0.0% 0.0% 0.0%
Opening Mouth 12.1% 25.8% 16.3% 25.0% 17.2% 16.7% 18.2% 13.3% 0.0% 0.0% 66.7%
Dry Mouth 60.6% 56.1% 54.9% 50.0% 48.5% 63.6% 59.6% 55.6% 11.1% 50.0% 33.3%
Sticky Saliva 31.8% 24.2% 24.2% 58.3% 28.3% 24.2% 23.2% 44.4% 11.1% 0.0% 0.0%
Coughing 30.3% 28.8% 24.2% 41.7% 22.2% 30.3% 23.2% 33.3% 0.0% 16.7% 50.0%
Felt Ill 12.1% 12.1% 8.5% 25.0% 15.2% 1.5% 5.1% 20.0% 0.0% 33.3% 0.0%
Pain Killers 36.4% 27.3% 29.4% 50.0% 33.3% 27.3% 24.2% 46.7% 33.3% 0.0% 50.0%
Nutritional Supplements 31.8% 27.3% 23.5% 75.0% 30.3% 22.7% 24.2% 33.3% 33.3% 50.0% 0.0%
Feeding Tube 4.5% 4.5% 0.0% 75.0% 6.1% 4.5% 0.0% 20.0% 0.0% 0.0% 0.0%
Weight Loss 13.6% 4.5% 9.8% 50.0% 21.2% 0.0% 9.1% 26.7% 0.0% 0.0% 0.0%
Weight Gain 22.7% 31.8% 27.5% 25.0% 21.2% 36.4% 27.3% 26.7% 33.3% 0.0% 50.0%
N Value 22 22 51 4 33 22 33 15 3 2 2
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Univariate analysis was then conducted on patient reported outcomes, once they had 
been transformed into standardized metrics, as detailed in the methods section. 
 
Multivariate analysis was then conducted for insurance type, HPV status, radiation 
treatment distance, and academic vs non-academic center while controlling for age, 
gender, stage, and treatment types. The results are presented below, with significant 
variables highlighted in green. 
 
In the data above, Insurance type was found to be significant for a number of factors. 
For all factors except dry mouth, the data presented was significant for private 
Gender Age Insurance Stage HPV status Treatment type Academic Center Treatment Distance
Pain 0.039 0.194 0.304 0.231 0.002 0.389 0.852 0.366
Swallowing 0.607 0.045 0.054 0.934 0.003 0.557 0.589 0.759
Senses Problems 0.384 0.025 0.25 0.003 0.026 0.792 0.024 0.028
Speech Problems 0.332 0.115 0.003 0.591 0.748 0.941 0.839 0.314
Trouble with Social 
Eating 0.641 0.255 0.081 0.773 0.157 0.947 0.151 0.046
Trouble with Social 
Contact 0.469 0.506 0.494 0.268 0.001 0.598 0.009 0.459
Less Sexuality 0.991 0.032 0.006 0.107 0.049 0.51 0.07 0.418
Teeth 0.092 0.053 0.543 0.38 0.07 0.841 0.045 0.028
Opening Mouth 0.05 0.475 0.182 0.589 0.217 0.568 0.674 0.02
Dry Mouth 0.594 0.499 0.17 0.566 0.574 0.008 0.009 0.959
Sticky Saliva 0.684 0.174 0.122 0 0.107 0.635 0.188 0.542
Coughing 0.383 0.131 0.462 0.566 0.142 0.525 0.145 0.536
Felt Ill 0.032 0.74 0.082 0.02 0.172 0.564 0 0.815
Pain Killers 0.007 0.216 0.625 0.647 0.403 0.979 0.634 0.518
Nutritional 
Supplements 0.324 0.417 0.439 0.999 0.058 0.519 0.538 0.741
Feeding Tube 0.496 0.472 1 0.999 0.997 0.983 0.809 1
Weight Loss 0.776 0.232 0.671 0.081 0.045 0.167 0.998 0.317





























Insurance 0.02 0.007 0.434 0.075 0.008 0.153 0.796 0.893 0.986 0.049 0.008 0.675 0.004 0.223 0.96 0.998 0.997 0.879
HPV 0.276 0.004 0.046 0 0.004 0.026 0 0.46 0.09 0.628 0.123 0.387 0.382 0.893 0.119 0.995 0.029 0.752
Academic 0.784 0.686 0.88 0.429 0.272 0.045 0.187 0.711 0.972 0.154 0.732 0.372 0.031 0.873 0.44 0.873 0.998 0.203
Radiation Distance 0.801 0.832 0.066 0.391 0.205 0.061 0.579 0.347 0.06 0.657 0.426 0.529 0.818 0.671 0.682 0.969 0.497 0.679
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insurance vs Medicare only. For dry mouth, it was found to be significant when 
comparing private insurance to Medicaid patients. 
Conclusion 
National Data 
Patients diagnosed with a head or neck cancer often have a difficult and protracted 
course of treatment before them. Many patients seek additional information about 
their prognosis, as well as how their particular institution performs. In this study, 
systemic analysis of what information was available to patients at the NCI designated 
Cancer Centers across the country was obtained. In addition, it was shown that it is 
feasible to construct an informational book that would provide data in accordance with 
American Association of Head and Neck Surgery guidelines. 
In the analysis of the 62 cancer centers across the United States, it was shown that there 
was minimal data regarding their cancer center’s structural, process, and outcomes 
metrics that was available to the public. Cancer centers that provide any quality and 
outcomes metrics accessible to patients should be commended, but this study shows 
that there is great opportunity to improve transparency, reporting, and data to 
patients.  The United Kingdom, and parts of Canada have much more sophisticated 
means of measuring and publicly reporting outcomes to guide decision-making and 
policy with the goal of optimizing H&N cancer care across the country.  This paper 
proposes a system whereby H&N cancer programs at the 62 NCI-designated cancer 
centers could voluntarily but systematically, report a particular set of H&N specific 
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structural, process, and outcome metrics for public consumption.  The initial goal would 
be for benchmarking and transparency, with the ultimate goal being to elevate the 
quality and outcomes of head and neck cancer care at each of these sites and possibly 
throughout the country. 
Yale Data 
In the analysis of Yale data, it was shown using tumor registry data was both reliable and 
feasible for a number of metrics. The registry data was able to isolate patients who had 
head and neck cancer, as well as provide comprehensive data on a number of metrics. 
In addition to general demographic data, the tumor registry was able to provide detailed 
information regarding key process metrics, as well as some morbidity and mortality 
information. However, many of the outcomes metrics that are most relevant to head 
and neck cancer patients were not catalogued by the tumor registry, and had to be 
found by chart review. 
The outcomes books demonstrated that the demographic data regarding head and neck 
patients was in line with national statistics regarding patients. In addition, the functional 
data regarding survival rates was also in line with national statistics. However, it also 
showed that there are several areas in which improvements could be made. Most 
notably, in many of the process metrics related to monitoring and treatment by ancillary 
staff, there were very few patients who were seen at an appropriate time, whether it 
was pre-treatment, during treatment, or post-treatment. There is no national data 
available regarding these metrics, so it is unclear if the program at Yale is an outlier, or if 
it is line with other cancer centers. At Yale, steps have already been taken to start 
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remedying these issues. A smoking cessation specialist has been hired, and physicians 
are now working more closely with speech pathologists, nutritionists, audiologists, and 
other ancillary staff to provide more comprehensive care.  
Oropharyngeal Patients 
The demographic data for the oropharyngeal patients analyzed were in line with national data, 
with a higher rate of cancer among males, usually between 55 and 75. There was also a much 
higher rate of HPV positive cancers as well as late stage cancers, which is again in line with 
national data. The outcomes data for one year survival, as well as recurrence rates were also in 
line with national data. Much of the other data could not be compared to national data, because 
it does not exist, to our knowledge. 
The data analysis demonstrated many different effects, but was also notable for the 
areas in which it did not demonstrate a difference. The data demonstrated that rates of 
alcoholism were higher for Medicare patients compared to patients with private 
insurance. This could demonstrate that patients on Medicare need to be monitored 
more carefully for alcoholic tendencies and treated as soon as possible, so that it 
interferes with their treatment as little as possible. The HPV positive patients 
demonstrated improved overall survival, disease specific survival, and disease free 
survival, which is consistent with national data regarding survival rates. It also 
demonstrated smaller rates of hearing loss when treated with cisplatin. This could 
indicate that patients with HPV negative cancer need to be monitored more carefully 
during chemotherapy to make sure they are receiving adequate hydration and other 
preventative measures to limit the toxicity of cisplatin. Finally, HPV negative patients 
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were much more likely to be smokers during and after treatment. As almost all 
oropharyngeal cancers are caused by either HPV or smoking, it seems clear that patients 
who had an HPV negative cancer would be more likely to be smokers. Interestingly, 
academic vs non-academic center demonstrated no difference in any functional 
outcome metric, demonstrating that care in terms of these metrics is equivalent. Finally, 
the analysis also demonstrated that recurrence rates in oropharyngeal patients were 
higher for patients that lived over 15 miles away. This may indicate that patients who 
live further away from their treatment sites may miss more appointments, or are unable 
to get proper follow-up as much as patients who live closer to their treatment site. 
However, further analysis must be conducted. 
Patient Reported Outcomes 
Patient reported outcomes showed differences in outcomes in several different areas. 
Private insurance patients were much less likely than Medicare patients to suffer from 
high rates of pain, swallowing difficulty, trouble with social eating, sticky saliva, and 
feeling ill. These factors can be monitored more closely for Medicare patients, to 
alleviate the issues they have with their treatment. The data also demonstrated that 
private practice patients were much more likely to have dry mouth compared to 
Medicaid patients. Dry mouth is a problem many patients suffer from after radiation 
treatment, and should be monitored for in all patients. The patients who were HPV 
positive had noticeably better patient reported outcomes in a number of metrics, 
including swallowing, senses problems, speech problems, social eating, social contact, 
and weight loss.  As with the issues HPV negative patients had in terms of functional 
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outcomes, they can be monitored for these issues more closely. The one area in which 
HPV positive patients did worse was in terms of decreased sexuality. This could be due 
to a number of factors that were not accounted for, such as whether one group was 
more likely to have a partner or engage in sexual behavior prior to treatment. 
Patient reported outcomes demonstrated that distance to radiation treatment site did 
not have significant impact on quality of life. However, in various categories, patients 
who received some of their treatment at non-academic centers had better quality of 
life. This could indicate that long term outcomes when there is adjuvant therapy at non-
academic centers are superior to outcomes when treatment is exclusively at academic 
centers. However, other possibilities include that the sample size was insufficient or that 
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